헤파린 시장(2026-2030년)

The global heparin market is forecasted to grow by USD 4108.8 mn during 2025-2030, accelerating at a CAGR of 7.7% during the forecast period. The report on the global heparin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of coagulation disorders, growing prevalence of chronic conditions, reintroduction of alternative sources to produce heparin.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global heparin market is segmented as below:

By Product

• Low-molecular-weight heparin
• Unfractionated heparin
• Ultra-low-molecular-weight heparin

By Route Of Administration

• Subcutaneous injection
• Intravenous infusion

By Source

• Porcine
• Bovine
• Synthetic

Geography

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• North America
  • US
  • Canada
  • Mexico
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the increasing research and development activities and new therapeutic applications of heparin as one of the prime reasons driving the global heparin market growth during the next few years. Also, advent of biosimilar low-molecular-weight heparin and rise in funding for heparin and supply chain expansion will lead to sizable demand in the market.

The report on the global heparin market covers the following areas:

• Global heparin market sizing
• Global heparin market forecast
• Global heparin market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global heparin market vendors that include Aspen Pharmacare Ltd., B.Braun SE, Baxter International Inc., Bioiberica S.A.U., Celsus Laboratories Inc., CZ Pharma, Fresenius Kabi AG, Gland Pharma Ltd, Hepalink Group, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos ROVI, LEO Pharma AS, NKF Pharma, Opocrin S.p.A., Pfizer Inc., PharmaAction Ltd, Sagent Pharmaceuticals Inc., Syntexa Pharmaceuticals Inc., TRENDING PHARMACEUTICALS, Yino Pharma Ltd. Also, the global heparin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Source
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Heparin Market 2020 - 2024
  • Historic Market Size - Data Table on Global Heparin Market 2020 - 2024 ($ million)
• 5.2 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.3 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.4 Source segment analysis 2020 - 2024
  • Historic Market Size - Source Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI in the Global Heparin Market
• 6.2 Impact of Geopolitical Conflicts on the Global Heparin Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product

• 8.1 Market segments
• 8.2 Comparison by Product
• 8.3 Low-molecular-weight heparin - Market size and forecast 2025-2030
• 8.4 Unfractionated heparin - Market size and forecast 2025-2030
• 8.5 Ultra-low-molecular-weight heparin - Market size and forecast 2025-2030
• 8.6 Market opportunity by Product
  • Market opportunity by Product ($ million)

9 Market Segmentation by Route of Administration

• 9.1 Market segments
• 9.2 Comparison by Route of Administration
• 9.3 Subcutaneous injection - Market size and forecast 2025-2030
• 9.4 Intravenous infusion - Market size and forecast 2025-2030
• 9.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

10 Market Segmentation by Source

• 10.1 Market segments
• 10.2 Comparison by Source
• 10.3 Porcine - Market size and forecast 2025-2030
• 10.4 Bovine - Market size and forecast 2025-2030
• 10.5 Synthetic - Market size and forecast 2025-2030
• 10.6 Market opportunity by Source
  • Market opportunity by Source ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 Europe - Market size and forecast 2025-2030
  • 12.3.1 Germany - Market size and forecast 2025-2030
  • 12.3.2 UK - Market size and forecast 2025-2030
  • 12.3.3 France - Market size and forecast 2025-2030
  • 12.3.4 Italy - Market size and forecast 2025-2030
  • 12.3.5 Spain - Market size and forecast 2025-2030
  • 12.3.6 The Netherlands - Market size and forecast 2025-2030
• 12.4 North America - Market size and forecast 2025-2030
  • 12.4.1 US - Market size and forecast 2025-2030
  • 12.4.2 Canada - Market size and forecast 2025-2030
  • 12.4.3 Mexico - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 South Africa - Market size and forecast 2025-2030
  • 12.6.6 Argentina - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing prevalence of coagulation disorders
  • Growing prevalence of chronic conditions
  • Reintroduction of alternative sources to produce heparin
• 13.2 Market challenges
  • Various side effects of heparin directly hinder its widespread adoption
  • Increase in shortage of raw heparin
  • Frequent product recalls are declining market demand
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Increasing research and development activities and new therapeutic applications of heparin
  • Advent of biosimilar low-molecular-weight heparin
  • Rise in funding for heparin and supply chain expansion

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Aspen Pharmacare Ltd.
  • Aspen Pharmacare Ltd. - Overview
  • Aspen Pharmacare Ltd. - Business segments
  • Aspen Pharmacare Ltd. - Key offerings
  • Aspen Pharmacare Ltd. - Segment focus
  • SWOT
• 15.5 B.Braun SE
  • B.Braun SE - Overview
  • B.Braun SE - Product / Service
  • B.Braun SE - Key offerings
  • SWOT
• 15.6 Baxter International Inc.
  • Baxter International Inc. - Overview
  • Baxter International Inc. - Business segments
  • Baxter International Inc. - Key offerings
  • Baxter International Inc. - Segment focus
  • SWOT
• 15.7 Bioiberica S.A.U.
  • Bioiberica S.A.U. - Overview
  • Bioiberica S.A.U. - Product / Service
  • Bioiberica S.A.U. - Key offerings
  • SWOT
• 15.8 Celsus Laboratories Inc.
  • Celsus Laboratories Inc. - Overview
  • Celsus Laboratories Inc. - Product / Service
  • Celsus Laboratories Inc. - Key offerings
  • SWOT
• 15.9 CZ Pharma
  • CZ Pharma - Overview
  • CZ Pharma - Product / Service
  • CZ Pharma - Key offerings
  • SWOT
• 15.10 Gland Pharma Ltd
  • Gland Pharma Ltd - Overview
  • Gland Pharma Ltd - Product / Service
  • Gland Pharma Ltd - Key offerings
  • SWOT
• 15.11 Hepalink Group
  • Hepalink Group - Overview
  • Hepalink Group - Product / Service
  • Hepalink Group - Key offerings
  • SWOT
• 15.12 Hikma Pharmaceuticals Plc
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key news
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Segment focus
  • SWOT
• 15.13 Laboratorios Farmaceuticos ROVI
  • Laboratorios Farmaceuticos ROVI - Overview
  • Laboratorios Farmaceuticos ROVI - Business segments
  • Laboratorios Farmaceuticos ROVI - Key offerings
  • Laboratorios Farmaceuticos ROVI - Segment focus
  • SWOT
• 15.14 LEO Pharma AS
  • LEO Pharma AS - Overview
  • LEO Pharma AS - Product / Service
  • LEO Pharma AS - Key offerings
  • SWOT
• 15.15 NKF Pharma
  • NKF Pharma - Overview
  • NKF Pharma - Product / Service
  • NKF Pharma - Key offerings
  • SWOT
• 15.16 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.17 PharmaAction Ltd
  • PharmaAction Ltd - Overview
  • PharmaAction Ltd - Product / Service
  • PharmaAction Ltd - Key offerings
  • SWOT
• 15.18 Yino Pharma Ltd
  • Yino Pharma Ltd - Overview
  • Yino Pharma Ltd - Product / Service
  • Yino Pharma Ltd - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations